The burden of dengue fever and chikungunya in southern coastal Ecuador: Epidemiology, clinical presentation, and phylogenetics from a prospective study in Machala in 2014 and 2015

Anna M. Stewart-Ibarra[1,2,*], Sadie J. Ryan[1,3,4,5], Aileen Kenneson[1], Christine A. King[1,6], Mark Abbott[1], Arturo Barbachano-Guerrero[6], Efraín Beltrán-Ayala[7], Mercy J. Borbor-Cordova[8], Washington B. Cárdenas[8], Cinthya Cueva[1], Julia L. Finkelstein[9], Christina D. Lupone[1], Richard G. Jarman[10], Irina Maljkovic Berry[10], Saurabh Mehta[9], Mark Polhemus[1,2], Mercy Silva[11], and Timothy P. Endy[1,2,6]

[1] Center for Global Health & Translational Sciences, SUNY Upstate Medical University, Syracuse, NY, USA

[2] Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

[3] Department of Geography, University of Florida, Gainesville, FL, USA

[4] Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA

[5] College of Life Sciences, University of Kwazulu-Natal, Durban, South Africa

[6] Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA

[7] Department of Medicine, Universidad Técnica de Machala, Machala, El Oro Province, Ecuador

[8] Department of Marine Engineering, oceanic and biological sciences, and natural resources. Escuela Superior Politecnica del Litoral (ESPOL), Guayaquil, Ecuador

[*] Corresponding author: Center for Global Health & Translational Science, State University of New York (SUNY) Upstate Medical University, 505 Irving Ave., Syracuse, NY 13210 USA; Email: stewarta@upstate.edu; Phone: +1 315 464 6489

[9] Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA

[10] Viral Diseases Branch of the Walter Reed Army Institute of Research (WRAIR), Silver Springs, MD, USA

[11] Ministry of Health, Machala, El Oro, Ecuador

Running head: The burden of dengue and chikungunya in Ecuador

Key words: dengue fever, chikungunya, *Aedes aegypti*, Ecuador, surveillance

Word count: Abstract: 243; Text: 7093; Figures: 7; Tables: 6; Supplementary Tables: 5

Abstract

Here we report the methods and findings from an arbovirus surveillance study conducted in the city of Machala, Ecuador, from January 1, 2014 to December 31, 2015. Patients with suspected DENV infections (index cases, n=324) were referred from five Ministry of Health sentinel clinics. A subset of DENV positive index cases (n = 44) were selected, and individuals from the index household and four neighboring households within a 200-meter radius (associates) were recruited (n = 400). In 2014, 70.9% of index cases and 35.6% of associates had evidence of acute or recent DENV infections. In 2015, 28.3% of index cases and 12.8% of associates had acute or recent DENV infections. For every DENV infection detected by passive surveillance, we detected an additional three acute or recent DENV infections in associates. Of associates with acute DENV infections, 68% reported dengue-like symptoms, with the highest prevalence of febrile acute infections in children under 10 years of age. The first CHIKV infections were detected on epidemiological week 12 in 2015. 41% of index cases and 4.6% of associates had acute CHIKV infections. No ZIKV infections were detected. Phylogenetic analyses of isolates of DENV from 2014 revealed genetic relatedness and shared ancestry of DENV1, DENV2 and DENV4 genomes from Ecuador with those from Venezuela and Colombia, indicating presence of viral flow between Ecuador and surrounding countries. Enhanced surveillance studies, such as this, provide high-resolution data on the distribution of symptomatic and subclinical arboviral infections across the population.

Introduction

The region of the Americas is facing an unprecedented public health crisis of co-occurring epidemics of illness due to dengue virus (DENV), chikungunya virus (CHIKV) and Zika virus (ZIKV). These arboviruses cause acute febrile illness, and are transmitted to humans primarily by the female *Aedes aegypti* and *Aedes albopictus* mosquitoes.

Dengue disease is caused by infection by one of the four serotypes of the mosquito-borne dengue virus (DENV 1-4), RNA viruses belonging to the family *Flaviviridae* genus *Flavivirus*. Clinical manifestations range from mild disease (*i.e.*, fever, rash, and joint pain) to severe illness characterized by pathologic vascular permeability leading to hemorrhage, shock, and sometimes death.[1] Over the last three decades, the distribution, severity, and incidence of DENV has increased in Latin America, from 16.4 cases per 100,000 in the 1980's to 71.5 cases per 100,000 from 2000 to 2007.[2,3] Current estimates of apparent DENV infection in the Americas range from 1.5 million[4] to 13.3 million[5] infections per year. In 2015, 2.35 million DENV infections were reported in the Americas, leading to 10,200 severe dengue infections and 1,181 deaths.[6]

More recently, CHIKV and ZIKV have emerged, and are now causing major epidemics in the same populations in the Americas. The first CHIKV infections (family *Togaviridae*, genus *alphavirus*) were reported in the Americas in 2013, resulting in over two million cases to date.[7] The first ZIKV infections (family *Flaviviridae*, genus *flavivirus*) were reported in Brazil in 2015.[8,9] To date, 801,589 suspected and confirmed autochthonous cases of ZIKV have been reported from the Americas (as of Sept 21, 2017).[10]

In Ecuador, DENV causes the greatest burden of mosquito-borne febrile illness. Historically, DENV was eradicated from Ecuador in the 1950s with support from the Rockefeller Foundation and the Pan American Sanitary Bureau, primarily through the use of DDT to control

Ae. aegypti, the only known vector in Ecuador.[11,12] Following a weakening of the vector control program and the re-invasion of *Ae. aegypti* in the 1970s and 1980s, DENV1 re-emerged in Ecuador in 1988, and caused a major epidemic of classic dengue fever.[13] From 1993 to 1999 three serotypes circulated: DENV1, DENV2 (American strain), and DENV4**.** In 2000, DENV3 and DENV2 (Asian strain) were identified and the first cases of severe hemorrhagic dengue were subsequently reported.[14]

Today the burden of DENV is greatest in the coastal lowland region of Ecuador, the site of the current study, where the disease is hyper-endemic and DENV1-4 co-circulate. Over a five-year period (2010 to 2014), 72,060 cases of dengue were reported in Ecuador, with an annual average of 14,412 cases.[15] Prior studies in southern coastal Ecuador indicate that DENV transmission is highly seasonal, with the greatest incidence of disease and density of mosquito vectors during the hot, rainy season from February to May, and lower transmission throughout the rest of the year.[16,17] DENV epidemics in the region are associated with El Niño climate events that cause increased rainfall and warmer air temperatures.[16] Local social-ecological risk factors for DENV infections and *Ae. aegypti* proliferation include poor housing conditions, interruptions in the piped water supply in the urban periphery, lack of knowledge of DENV transmission, and water storage behavior.[17–19]

The first autochthonous CHIKV infections were reported in Ecuador at the end of 2014, resulting in a major epidemic in 2015, with over 33,000 cases reported. The first autochthonous ZIKV infections were confirmed in Ecuador on January 7, 2016. A total of 6,811 suspected and confirmed cases of ZIKV have been reported to date (as of Sept 11, 2017), including seven cases of congenital syndrome associated with ZIKV, the first of which were reported in May 2017.[10]

In Ecuador, suspected and confirmed DENV, ZIKV, and CHIKV cases require mandatory notification to the Ministry of Health (MoH). The MoH in Ecuador follows the 2009 WHO dengue diagnostic guidelines.[1] The national surveillance system is based on passive surveillance of cases from MoH clinics and hospitals, which provide free healthcare to the population. A subset of suspected cases are confirmed for DENV using NS1 and IgM ELISAs in local diagnostic laboratories operated by the MoH, and some cases are confirmed for DENV, CHIKV, ZIKV using quantitative PCR at the national reference laboratory of the National Institute for Public Health Research (INSPI) of the MoH. Positive cases trigger focal vector control interventions in the infected home and surrounding homes by the MoH (i.e., fogging, indoor residual spraying, source reduction, and larvicide application).

There have been prior enhanced surveillance studies to estimate the burden of dengue fever in Asia[20–23] and Latin America[24–29], with study designs ranging from pediatric to adult cohorts, tracking of school-based absentees, use of sentinel clinics, and community-based cluster investigations. In general, these studies found that enhanced surveillance methods identified a greater number of DENV infections, especially mild and subclinical infections, compared to traditional passive surveillance systems. Enhanced surveillance studies generate high-resolution information on the spatial and temporal distribution of infections and illness across the population. This is especially important in settings and in subgroups with low-health care seeking behavior or limited access to health centers. These data allow the public health sector to more accurately estimate the social and economic burden of the disease, allowing for more informed decision-making regarding the allocation of scarce resources. These studies can also inform the design and implementation of interventions targeted at high-risk groups, such as vaccination campaigns or vaccine trials.

The aim of this study was to characterize the epidemiology and clinical presentation of DENV and CHIKV, and the viral phylogenetics of DENV from the city of Machala, Ecuador, in 2014 and 2015. Patients with acute DENV infections (index cases) were recruited from sentinel clinics and the central hospital. Index cases triggered active surveillance of DENV, CHIKV and ZIKV infections in individuals (associates) living within 200 meters of the index patient. We focus specifically on: (1) the epidemiological characterization of DENV and CHIKV infections in index cases and associates, (2) estimation of expansion factors for DENV infections, and (3) phylogenetic analysis of DENV circulating in 2014. This study contributes to an ongoing collaboration with the MoH of Ecuador to strengthen febrile vector-borne disease surveillance in southern coastal Ecuador, providing high resolution epidemiological information for the region.[30]

Materials and Methods

Definitions

Index cases are hospitalized patients and outpatients with a clinical diagnosis of an acute DENV infection who enrolled in the study. *Associates* are study subjects who resided in the household of the index case and/or four homes within 200 meters of the index case household. The four neighboring homes plus the home of the index case are referred to as a *cluster*.

A study subject was considered to have an *acute DENV infection* if s/he tested positive by NS1 rapid test, NS1 ELISA or RT-PCR. If the person was negative for those three tests, but had anti-dengue IgM antibodies, they were classified as having a *recent DENV infection*. Individuals were classified as *uninfected with DENV* if they were negative for NS1 rapid test, NS1 ELISA, RT-PCR and IgM ELISA. Individuals who tested negative for all of the tests except for the

presence of IgG antibodies were not classified. Individuals who tested positive for CHIKV or ZIKV by RT-PCR were classified as having an *acute CHIKV or acute ZIKV infection*.

Febrile was defined as either self-reported fever within the last 7 days or measured fever (>38°C) upon entering the study.

For the expansion factor calculations, we define a *symptomatic* individual as an associate with one or more dengue-like symptoms. By definition, all index cases are symptomatic. Prior studies that report symptomatic illness, defined symptomatic as febrile,[23,31] whereas we use a broader definition of symptomatic to include any dengue-like symptom (e.g., headache, muscle/joint pain, retro-orbital pain, abdominal pain, drowsiness/lethargy, fever, rash), since symptoms other than fever were more frequently reported by associates with acute DENV infections (Supplementary Table 1). *Asymptomatic* is defined as an associate without any dengue-like symptom.

Ethics Statement.

This protocol was reviewed and approval by Institutional Review Boards (IRBs) at SUNY Upstate Medical University, Cornell University, the Human Research Protection Office (HRPO) of the U.S. Department of Defense, the Luis Vernaza Hospital in Guayaquil, Ecuador, and the Ecuadorean Ministry of Health. Prior to the start of the study, all participants engaged in a written informed consent or assent process, as applicable. In the event the participant was unable to participate in the informed consent or assent process, a recognized health-care proxy represented them in the process and documented consent. Children aged 7 to 17 signed an assent statement and parents signed an informed consent. Parents signed an informed consent on behalf of children under the age of 7 years to > 6 months. The study population included children (> 6

months) to adults (index cases) who were evaluated in sentinel clinics or the hospital with a clinical diagnosis of acute DENV infection. Before signing the informed consent, index cases were informed that they might be randomly selected to participate in a cluster investigation. Additional study subjects include associates, who were children (> 6 months) and adults who resided in the household of the index case and homes within 200 meters of the index case household.

Study Site.

Machala, Ecuador, (population 280,694, capital of El Oro Province) is a mid-sized coastal port city located along the Pan American Highway, 70 kilometers north of the Ecuador-Peru border (Fig 1). Machala has among the highest incidence rates of DENV in Ecuador, and prior studies reported the highest *Ae. aegypti* densities compared to sites from 10 countries in Latin America and Asia.[17,32,33] In 2014 and 2015, 1,196 and 2,791 dengue cases, respectively, were reported from Machala (mean annual incidence 42.6 and 99.4 cases per 10,000 people).[34] The first cases of CHIKV were reported by the MoH in May of 2015, and the first cases of ZIKV were reported in February of 2016. Based on the high volume of people and goods moving across the border and the historically high incidence of DENV, Machala is a strategic location to monitor and investigate DENV -- and now CHIKV and ZIKV -- transmission dynamics.

Sentinel clinics operated by the MoH in Machala were selected based on the number of reported DENV cases and the resources that they were able to offer for coordinating and supporting the methods of this surveillance study. Of the twenty-three MoH clinics in Machala, four were selected. These included the clinics Brisas del Mar, Rayito de Luz, Mabel Estupiñan, and El Paraiso. In addition, the Teófilo Dávila Hospital of the MoH was included, because it is

the principal public hospital of the province, where the MoH clinics refer patients with severe DENV infections.

Passive and active surveillance study design.

Hospitalized patients and outpatients with a clinical diagnosis of an acute DENV infection (index cases), as determined by MoH physicians, were referred to our study technician or nurse at the hospital. All patients that were referred to the study team were invited to participate in the study. Informed consent was obtained and the following data were collected using a customized database on an Ipad (FileMaker Pro Advanced 13.0v5): demographic information including home address, primary reason for hospitalization, date of onset of fever, symptoms within the last seven days, medications, and aural temperature. Data were uploaded daily and stored in a secure cloud-based server (GoZync). At the time of clinical evaluation a 20 ml blood specimen (adjusted for age and weight by the National Institute of Health criteria) was obtained by venipuncture from each participant. Samples were processed at our diagnostic laboratory at the hospital. Serum samples were used to test for acute dengue infections using NS1 rapid strip tests (PanBio Dengue Early Rapid Test; sensitivity: 91.89%, specificity: 98.39%). NS1 tests were run the same day that the index case was recruited into the study. Additional serum, cells and plasma were separated via centrifugation and aliquoted in multiple tubes and stored at -80°C.

Each week, up to four index cases that were confirmed to be positive for DENV infection by NS1 rapid strip test were randomly selected and invited to participate in the active surveillance component of this study. The study team visited the household of the index case, and invited members of the household to participate. The study team then invited individuals to

participate (associates) who resided in the nearest neighboring homes in each of the four cardinal directions within a 200-meter radius of the index household, the typical flight range of the *Ae. aegypti* mosquito. The neighboring homes plus the index home are referred to as a cluster. Investigations in clusters were initiated within two days of the index case entering the study. The diagnostic tests and clinical assessments described above for index cases were repeated for all associates. The location (latitude, longitude) of each home was recorded using handheld Garmin GPS units. Passive and active surveillance study designs were optimized in a prior study by the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Kamphaeng Phet Province, Thailand.[23]

Diagnostic assays.

Additional diagnostic testing for DENV was conducted using serum samples and commercial ELISA kits (Panbio) to test for NS1 (Dengue Early ELISA), IgM (Dengue Capture IgM), and IgG (Dengue Capture IgG). Participants were classified as having "primary" infection if the IgM to IgG ratio was ≥ 1.8 and "secondary" infection if the ratio was < 1.8.[23,35,36]

Specimens were shipped to SUNY Upstate Medical University for testing by qualitative real-time reverse transcriptase (RT)-PCR assays for DENV1-4 and ZIKV / CHIKV. All samples from 2014 and 2015 were screened for DENV1-4. Samples from index cases in 2014 and 2015 were screened for CHIKV. Only samples from 2015 were screened for ZIKV. All analyses were performed on a BioRad DNA Engine Chromo 4 System with MJ Opticon Monitor Analysis Software. For DENV1-4 analysis, total RNA was extracted from 140 µL of human serum specimens using the QIAamp® Viral RNA Mini Kit (QIAgen, Cat# 52906) according to the manufacturer's suggested protocol and resuspended in 50 µL of buffer. Ten (10) µL of RNA (or

the equivalent of 28 µL of serum) was used ina 20 µL reverse transcriptase reaction, of which 5 µL of the resulting cDNA was used for the PCR reaction. All samples and controls were analyzed in duplicate in a multiplex RT-PCR reaction for 45 cycles using SuperScript III Platinum One-Step qRT-PCR System (Life Technologies Cat# 11732-020) based on the CDC DENV1-4 Real Time RT-PCR Assay (CDC, Catalog number KK0128) and a published assay[37] (primers and probes in Supplementary Table 1). Samples were classified as positive according to a suggested C(t) value of ≤ 37.00, which coincides with a cutoff based on CDC recommendations for identifying positive DENV samples. For ZIKV and CHIKV analysis, total RNA was extracted from human serum specimens using the QIAamp® Viral RNA Mini Kit (QIAgen, Cat# 52906) according to a modified assay developed at the Walter Reed Army Institute of Research (WRAIR), Viral Diseases Branch. All samples and controls were analyzed in duplicate in a multiplex RT-PCR reaction using TAQMAN Fast Virus 1-Step Mix (Life Technologies Cat# 4444432). The CHIKV primer/probe set (HEX reporter) was adapted from Armed Forces Research Institute of Medicine Sciences (AFRIMS) protocol, Set 3, which was designed specifically for the Asian genotype CHIK strain currently in the Caribbean and verified using Synthetic CHIKV RNA control (ATCC, Cat# VR-3246SD). The ZIKV primer/probe set (FAM reporter) was based on the AFRIMS protocol that was adapted from a published assay[38] and verified using RNA extracted from ZIKV culture fluid (ZeptoMetrix Corp., Cat# 0810092CF). Both primer/probe sets were specific for their respective viral target and did not detect other viruses (DENV1-4, YFV, and JEV). Samples were classified as positive based on the same cutoff value used for DENV (C(t) value of ≤37.00). Primers and probes for DENV, CHIKV, and ZIKV are shown in Supplementary Table 2.

Statistical analysis.

Statistical analyses were conducted using R (version 3.3.3) in RStudio (version 1.0.136), using the 'base' and 'psych' packages for summary statistics. Student's t-test was used to determine differences in continuous variables, and Chi-square or Fisher's exact test were used for proportions.

We calculated expansion factors (EF) for all acute and recent DENV infections, all acute DENV infections, and symptomatic acute DENV infections. The DENV expansion factor (EF) is the ratio of the best estimate of DENV infections (often from active surveillance) to the number of reported cases (often from passive surveillance).[39] An EF = 1 reflects 100% reporting of DENV infections, and EF > 1 indicates underreporting.[39] There are a variety of methods used to calculate EFs in the literature[4,39–41], using different data sources and study designs, from cluster-based small cohort methods to large scale (national-level) surveillance data corrections. We estimated expansion factors (EF) by dividing the number of DENV infections in associates by DENV infections in index cases, plus reporting associates. Associates (n=2 in 2014) who reported seeking medical care for DENV infections in the past week were added to the denominator, as it is possible that they would have been captured by the MoH surveillance system. Thus, EF is:

$$\mathrm{EF} = \frac{\#\ \mathrm{DENV\ infections\ in\ the\ population\ tested)}}{(\mathrm{index\ case} + \#\ \mathrm{reporting\ associates})}$$

We calculated annual total estimates of EF, and present average (SD) values. We assume that the tested population is representative of the larger population, but acknowledge there may be unknown bias due to correlations between likelihood of infection and participation, in either direction.

Sequencing and consensus assembly.

Samples from 2014 that were DENV positive by RT-PCR were sent to Walter Reed Army Institute of Research (WRAIR), Viral Diseases Branch, for full-length sequencing. Samples were extracted using a QIAGEN QIAamp viral mini RNA extraction kit in accordance with manufacturer's protocols. Full genome was amplified on Fluidigm Access Array system using dengue serotype specific primers and the Life Technologies SuperScript TM III One-Step RT-PCR system with Platnimum® Taq High Fidelity polymerase, followed by cDNA quality check using Agilent Bioanalyzer DNA7500 kit and RT-PCR product purification. Purified RT-PCR products were quantified using the Invitrogen Quant-iTTM PicoGreen dsDNA Reagent and Kit following the manufacturer's protocols. MiSeq library preparation included: dilution of purified amplicons products to 0.2ng/µL, tagmentation using 5 microliters of each dilution stock as input DNA, neutralization of each Nextera® XT Tagmentation reaction using 5µl NT buffer, PCR amplification using index primers from Nextera XT Index kit version 2 set C, PCR clean up using 25 microliters per PCR reaction of Beckman Counter AMPure XP beads, and library normalization using applicable reagents provided in the Nextera XT® DNA Library Preparation kit. After normalization, each library was pooled and sequenced using the Illumina MiSeq reagent kit (version 2, 500 cycles) and Illumina MiSeq next generation sequencer in accordance with Illumina protocols.

Construction of consensus genomes was performed using ngs_mapper v1.2.4 in-house developed pipeline (available on github, http://dx.doi.org/10.5281/zenodo.46716). Briefly, raw fastq data were stripped of barcodes and adapters and subjected to read filtering using a quality threshold of Q25. Remaining reads were further end-trimmed using a quality threshold of Q25 using Trimmomatic.[42] Trimmed reads with quality >Q25 were initially mapped to a set of

reference sequences to determine the best reference fit for each of the samples. Following reference determination, reads from each of the samples were re-mapped to their closest related reference genome, to maximize the number of mapped reads. Reference mapping was performed using the BWA-MEM algorithm.[43] Assemblies were further processed using samtools version 0.1[44] and an in-house developed python program called *basecaller.py* to produce an adapted VCF for each segment, in parallel, which incorporates genomic ambiguity inherent in RNA viruses into the final consensus genome for that sample based on thresholds set by the investigator. Threshold for consensus genomic reconstruction for ambiguity incorporation was set at 20% for this analysis, meaning if any site contained a different nucleotide call that was present at 20% or greater in the dataset (taking quality of call into account) the site was given an ambiguous base call (according to IUPAC conventions). Consensus sequences for all samples were constructed, in parallel, from the adapted VCF output. All consensus sequences were further manually quality-checked. Statistics and graphics illustrating read depth and quality of mappings for each sample across each segment produced by the pipeline were done using matplotlib.[45]

Phylogenetic analyses.

The five sequenced full genome DENV1 samples were aligned to a set of full genome DENV1 reference sequences obtained from GenBank using MEGAv6.[46] The 131 reference genomes were selected to represent: i) all DENV1 genotype lineages, for accurate genotype determination, ii) wide sampling time periods, with a focus on the most recently sampled genomes (2009-2016), iii) most geographical regions, with a focus on Central and South America. In addition, the top 20 genomes matching the five genomes from Ecuador through

Basic Local Alignment Search Tool (Blast)[47] were added to the reference dataset. A set of 140 full genome DENV2 reference sequences was obtained from GenBank following the same criteria as for DENV1, and aligned to the 27 DENV2 sequenced genomes from Ecuador. Likewise**,** a set of 100 full genome DENV4 reference sequences was obtained from GenBank following the same criteria as for DENV1, and aligned to the single DENV4 sequenced genome from Ecuador. We were unable to sequence DENV3 due to limited sample volume. Genetic sequences have been deposited in GenBank under accession numbers KY474303-KY474335.

The best-fit models of evolution for DENV1, DENV2 and DENV4 datasets were determined using jModelTest v2.1.7 and chosen based on Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC).[48] Maximum Likelihood (ML) phylogenetic trees for each of the DENV1, DENV2 and DENV4 datasets were inferred using Phyml v 4.9.1.[49,50] The model of evolution used for the full genome tree inferences was GTR+I+Γ (general time reversible with empirically estimated proportion of invariant sites and gamma distribution of among-site variation, 4 categories), for all three dengue serotypes. The tree space was searched heuristically using the best of NNI (Nearest Neighbor Interchanges) and SPR (Subtree Pruning and Regrafting). Node confidence values were determined by aLRT (approximate Likelihood Ratio Test) using the nonparametric Shimodaira-Hasegawa approach. Node confidence values of >0.75 are considered good support. The resulting trees were rooted by the KR919820 sylvatic reference genome[51] for DENV1, and by the sylvatic genotype outgroups for DENV2 and DENV4.

Results

From January 1, 2014, through December 31, 2015, we recruited 324 index cases with suspected DENV infections from the five clinical sites in Machala, Ecuador (Figs 1 and 2). A subset of 310 index cases (186 in 2014, 124 in 2015) had valid test results and were included in this study (Table 1). A total of 72 index cases were positive by NS1 rapid test, and from these we randomly selected 44 index cases as initiates of clusters, from which 400 associates were recruited into the study. A subset of 384 associates (298 in 2014, 86 in 2015) had valid test results and were included in this study.

In 2014 and 2015, DENV transmission began in January and February, peaked in May, and tailed off in September and October (Fig 3). All four DENV serotypes were detected in 2014, with DENV2 as the predominant serotype (Table 2). In 2015, DENV1 and DENV2 were detected. CHIKV was first identified in our study on epidemiological week 12 in 2015, and transmission followed a similar seasonal curve as DENV (Fig 3). No ZIKV infections were detected (Table 1).

Table 1 shows the diagnostic results from 2014 and 2015. There were some individuals who did not have enough information to categorize as DENV positive or negative, for example, an individual who was negative for an NS1 rapid test and PCR, but did not have any ELISA or serology test results. To account for these discrepancies, prevalence estimates include people for whom test results were available, as indicated by the denominators in the diagnostic results section of the table.

Passive surveillance of index cases

In 2014, the majority of index cases (132/186, 70.9%) were positive for an acute or recent DENV infection (Table 1). Most infections were DENV2 (43/51, 84.3% of serotyped index

cases) and were secondary DENV infections (73/99, 73.7% of index cases with serology) (Tables 2 and 3). Index cases with acute DENV infections were on average 20 years old (SD=15.7) and 62.7% were male (Table 4). The majority reported a fever within the last 7 days (97.3%), and 21.3% had fever (>38°C) upon entering the study; 18.2% were hospitalized.

In 2015, more index cases were positive for acute CHIKV (50/122, 41%) than for acute or recent DENV (35/124, 28.3%). One index case was positive for both acute DENV and acute CHIKV, and five index cases were positive for recent DENV infections and acute CHIKV infections. DENV1 was the predominant serotype (13/22, 59.1% of serotyped index cases) (Table 2). Significantly more primary DENV infections were reported in 2015 than in 2014 (21/31, 67.7% of index cases with serology, $p<0.001$, Table 3). Index cases with acute DENV infections were on average 19.3 years old (SD=12.8), and 54.1% were female (Table 4). All index cases with acute DENV infections reported a fever within the last 7 days, 41.7% had fever upon entering the study, and 33.3% were hospitalized. There were no significant differences in the demographics, febrile symptoms, or hospitalization rates for index cases with acute DENV infections between 2014 and 2015 (Table 4, $p>0.05$).

We estimated the prevalence of febrile acute (FA) infections for DENV and CHIKV by age class as a proportion of the total number of individuals recruited per age class (Fig 4, see Supplementary Table 3 for prevalence calculations). Febrile was defined as either self-reported fever within the last 7 days or measured fever (>38°C) upon entering the study. Index children aged 10 to 19 years had the highest prevalence of FA DENV infections (40/98, 40.8%). In contrast, the prevalence of FA CHIKV infections increased with increasing age. Index cases aged 60 to 69 years had the highest prevalence of FA CHIKV infections (5/5, 100%).

We compared the demographics and symptoms of index cases with acute DENV versus CHIKV infections. Index cases with CHIKV infections were significantly older (35 years, SD=18.1, N=48) than those with DENV infections (20 years, SD = 15.0, N=98) ($p<0.0001$) (Table 5). Index cases with acute DENV infections were significantly more likely to report anorexia and nausea, vomiting, and abdominal pain, whereas index cases with CHIKV were more likely to report rash ($p<0.05$).

We also compared the demographics and symptoms of primary versus secondary DENV infections, and DENV1 versus DENV2 infections in index cases. Overall, we identified more severe illness in secondary DENV infections than in primary infections (Supplementary Table 4). Individuals with secondary DENV infections were significantly older, were more likely to be hospitalized, and were more likely to report vomiting ($p<0.05$). Individuals with primary DENV infections were more likely to report fever ($p<0.05$). We did not find significant differences in symptoms between DENV1 and DENV 2, the predominant serotypes detected in this study (Supplementary Table 5).

Active surveillance of associates

In each cluster of homes, approximately nine associates were recruited into this study per index case. The distance between the households of associates and the respective index households ranged from 2.2 to 164 meters, with an average of 39 meters (SD=29 m). Most associate households (95.4%) were within 100 meters of the index household.

In 2014, approximately one third of associates (106/298, 35.6%) had evidence of acute or recent DENV infections (Table 1). As with index cases, DENV2 was the dominant serotype (Table 2). A similar proportion of primary (46.9%) and secondary infections (53%) were

detected (Table 3). Similar to index cases, the prevalence of DENV infections decreased in 2015 (11/86 acute or recent infections, 12.85%). Only one associate was serotyped as DENV2, and four of six associates with serology had primary infections (66.7%). The serology of associates in 2014 versus 2015 was not significantly different due, in part, to the small sample size ($p>0.05$). In 2015 we detected acute CHIKV infections in four associates (4/87, 4.6%), including one associate with both acute CHIKV and recent DENV infections.

Approximately two thirds of associates with acute DENV infections (34/50, 68%) reported one or more dengue-like symptoms, *i.e.*, fever, rash, muscle or joint pain, abdominal pain or tenderness, bleeding, drowsiness or lethargy within the last 7 days (Supplementary Table 1). The most commonly reported symptoms were headache (32%), drowsiness/lethargy (24%), fever (22%), and muscle/joint pain (22%). No associates were hospitalized due to a DENV infection (Table 4). There were no significant differences in the demographics or febrile symptoms for associates with acute DENV infections between 2014 and 2015 ($p>0.05$).

For associates, we determined the prevalence of FA infections for DENV by age class (Fig 4, Supplementary Table 3). Associate children aged 0 to 9 years had the highest prevalence of FA DENV infections (3/25, 12%), and prevalence declined with age. No associates had FA CHIVK infections.

At the cluster level, prevalence rates varied by the DENV serotype of the index case. In 10 of 44 clusters, the index case had a DENV1 infection. In these clusters, 20% of associates had acute or recent DENV infections (12/60; 95% CI: 11.8-31.8%), with a range of 0% to 57.1%. The index case had a DENV2 infection in 17 of 44 clusters. Among these clusters, a significantly greater proportion of associates (36.6%; 59/161; 95% CI: 29.6-44.3%) ($p=0.02$) had an acute or recent DENV infections, with a range of 12.5% to 87.5%.

We report the expansion factors (EF) for acute and recent DENV infections, acute DENV infections, and symptomatic (*i.e.*, one or more dengue-like symptoms) acute DENV infections (Table 6). The EF calculations were adjusted to account for two associates with acute DENV infections in 2014 who sought medical care within the last 7 days. All EF measures were significantly greater in 2014 than in 2015 ($p<0.05$). The EF for acute and recent DENV infections was 3.14 (SD=2.22) in 2014 and 0.92 (SD=0.67) in 2015. The EF for acute DENV infections only was 1.33 (SD=1.49) in 2014 and 0.42 (SD=0.67) in 2015. The EF for symptomatic acute DENV infections was 0.89 (SD=1.05) in 2014 and 0.25 (SD=0.62) in 2015.

Phylogenetic analysis of DENV

The best-fit models for the evolution of DENV1, DENV2, and DENV4, as determined by AIC versus BIC, agreed in all instances. ML phylogenetic tree demonstrated a clear distinction of DENV1 genotypes *I*, *II*, *IV* and *V*, and the sylvatic genotypes *III* and *VI* (Fig 4). The five genomes from Ecuador, all sampled in 2014, belonged to genotype *V* of DENV1 and were found in the sub-lineage containing mainly Central and South American genomes (i.e., Colombia, Venezuela, Argentina, Brazil and Puerto Rico). More importantly, sequences from Ecuador fell into two distinct clades within this sub-lineage; two Ecuadorian genomes more closely related to genomes sampled in Argentina and Venezuela (Clade A), and three Ecuadorian genomes more closely related to a genome from Colombia (Clade B).

The ML phylogenetic tree of DENV2 showed a clear distinction of DENV2 genotypes, including sylvatic, American, Cosmopolitan, Asian I, Asian II and Asian/American (Fig 5). The samples from Ecuador were found within the Asian/American genotype, making up a monophyletic cluster (Clade A) separated from the rest of the South American taxa with high

support (aLRT = 1). Genomes clustering closest to the clade A from Ecuador were sampled in Colombia and Venezuela. Sequences from other neighboring countries, such as Peru and Brazil, were found further down in the Asian/American lineage and were separated from the clade A, and from sequences from Colombia and Venezuela, with high support (aLRT = 0.99).

The ML phylogenetic tree of DENV4 demonstrated a clear distinction of genotypes *I*, *IIA*, *IIB*, *III* and sylvatic (Fig 6). However, two taxa from India/1961-1962 clustered with genotype *I* with low support (aLRT=0.04), indicating their position in the tree was uncertain and they might belong to a different genotype. The single Ecuador sequence was located within the genotype *IIB* lineage (magenta in the tree). It was surrounded by sequences collected from Venezuela, Colombia and Brazil, indicating their common ancestry. However, the aLRT support for the Ecuador node was low (0.37) suggesting that its correct placement was uncertain.

Discussion

In this study, we characterized the epidemiology and clinical characteristics of CHIKV and DENV infections, and phylogenetics of DENV, through an enhanced surveillance study design in an endemic region. We found that burden of febrile acute (FA) DENV in associates was greatest in children under 10 years of age. In 2014, for every DENV infection detected by passive surveillance (index cases), we detected an additional three acute or recent infections in the community (associates). Of associates with acute DENV infections, two thirds presented with dengue-like symptoms. The burden of DENV decreased from 2014 to 2015 with the emergence of CHIKV. Genetic analyses indicate that there is movement of the dengue virus between Ecuador and neighboring countries, highlighting the importance of sentinel surveillance sites, such as Machala, in border regions.

Burden of DENV infection and EF estimates.

Over the two years of the study, 117 of 384 (30.4%) of associates had acute or recent DENV infections, a higher prevalence than findings from similar studies in Asia. In Vietnam, studies found 18% DENV prevalence in 100 meter clusters around index cases, using PCR, NS1 ELISA, or serology.[20] In Thailand, cluster DENV prevalence ranged from 10.1% to 14.3% using PCR or serology.[21,22] One of possible explanations for the higher cluster prevalence in this study is the use of the NS1 rapid strip test. We found that the prevalence of DENV infections in clusters varied by DENV serotype (DENV1: 20.0%; DENV2: 36.6%). The higher cluster prevalence for DENV2 is consistent with prior studies that found greater infection rates for DENV2 compared to DENV1.[52]

The expansion factor (EF) for DENV in Machala was estimated using acute/recent infections, only acute infections, and symptomatic acute infections as a proportion of the number of medically-attended infections among the 44 clusters. In 2014 and 2015, the mean EFs were 3.14 and 0.92 for all acute/recent DENV infections, 1.33 and 0.42 for acute DENV infections, and 0.89 and 0.25 for symptomatic acute DENV infections. These EFs are comparable to the low end of a range of previously reported EFs for the PAHO region.[39] Interestingly, we found that the EF was higher in 2014 than 2015, suggesting a higher force of infection in 2014. We temper this suggestion with caution, however, as our cluster sample size was smaller in 2015 (n=12) than 2014 (n=32). The rapid surveillance methods developed in this study could be applied to estimate the burden of other underreported febrile diseases, allowing the public health sector to more effectively and equitably conduct disease control interventions.

To our knowledge, most cluster-based DENV surveillance studies have been conducted in Asian countries. In Latin America, enhanced surveillance studies have focused on pediatric and adult cohorts, door-to-door community based surveillance, use of sentinel clinics, and enhanced laboratory diagnostics. Expansion factors estimates vary widely depending on the surveillance methods used, and the characteristics of the local population, including past exposure to DENV serotypes. In a pediatric cohort in Nicaragua, investigators detected 21.3 times more dengue infections than were reported to the national surveillance system.[53] A study in Peru compared passive surveillance of dengue to a cohort study and sentinel clinic surveillance, and estimated an EF of 5 for the cohort and an EF of 19 for the sentinel clinic surveillance.[24] They found that both sentinel and cohort surveillance methods detected an increase in dengue infections more rapidly than passive surveillance methods. In Puerto Rico, laboratory enhanced surveillance resulted in three times more infections registered than passive surveillance methods.[26]

One of the limitations of this study was that we surveyed the nearest neighbors of the index case, which are not necessarily representative of the total population residing within 200 meters. Also, people may have been more willing to participate in the study if they or someone in their household was ill. Future studies could survey a greater number of households located randomly within the 200-meter radius for a more accurate measure of disease prevalence. Additionally, this study was limited to five clinical sites operated by the MoH that were willing and able to support the study.

Burden of CHIKV and other febrile illness:

In 2015, we found that 41% (50/122) of clinically diagnosed DENV infections (index cases) were positive for CHIKV, higher than the proportion of laboratory-confirmed DENV infections. We identified six index cases (6/122=4.94%) and one associate (1/87=1.1%) with evidence of both acute CHIKV and acute or recent DENV infections in 2015. There were also 96 individuals with undiagnosed febrile illness (non-DENV, non-CHIKV, non-ZIKV). The burden of CHIKV is likely higher than reported here, since anti-body tests were not utilized. This highlights the difficulties of differential diagnosis in areas where DENV, CHIKV, ZIKV, and other febrile illnesses are co-circulating. These data also suggest that the large increase in DENV cases in 2015 reported by Pan American Health Organization (PAHO) and MoH in Ecuador (42,667 cases in 2015 versus 14,412 cases on average from 2010 to 2014)[15] could be the result of other circulating arboviruses, including CHIKV.

We did not detect ZIKV in our surveillance system during the study period, consistent with MoH reports, which indicated that ZIKV circulated for the first time in Machala in February 2016. Although surveillance efforts were not focused specifically on clinical ZIKV infections, we suspect that the study would have detected some ZIKV infections if they were present in Machala due to the overlapping clinical presentations of DENV and ZIKV infections. However, more recent studies shown that ZIKV may be more readily detected in urine and whole blood, limiting our ability to detect ZIKV in serum samples by RT-PCR.[54,55]

Clinical predictors of DENV and CHIKV.

In general, the symptoms that were observed with acute DENV infections in this study are consistent with other reports.[56–62] Consistent with prior studies, we found that secondary DENV infections had a higher proportion of severe outcomes including hospitalization, bleeding,

and vomiting.[23,61,63] The symptoms associated with DENV infections can vary over time and space due to both differences in the dominant serotypes in circulation[64,65] and the ratio of primary to secondary infections.[23,61,63]

People infected with CHIKV versus DENV were older on average, consistent with the disease being newly introduced into the population. MoH reports indicated that the highest burden of CHIKV in Machala was among adults aged 20 to 49. We found that rash was more commonly reported by people with CHIKV infections than those with DENV, which is consistent with previous reports.[58,62]

We found that two thirds of associates with acute DENV infections were symptomatic; however, only two individuals had sought medical care. In Machala, community members reported that men in the urban periphery were less likely to seek healthcare,[18] and medical professionals confirmed a high degree of self-medication and underreporting of DENV.[66] Use of a broader definition symptomatic to include any dengue-like symptom, rather than only fever, allowed us to capture a broader spectrum of DENV illness.[31] In associates, the ratio of symptomatic acute DENV infections to subclinical infections was 1:0.47, similar to prior studies.[23,31] These findings highlight the importance of active surveillance protocols that capture subclinical infections and infections in demographic groups who do not seek health care.

Phylogenetic analysis

Phylogenetic analyses of DENV1 showed Ecuadorian samples falling into two distinct clusters, sharing a common ancestor with viruses from Colombia in one cluster and a common ancestor with viruses from Venezuela in the other one. These well-separated clusters indicate at least two distinct introductions of DENV1 into Ecuador. Given the early sampling of Venezuelan

and Colombian genomes (between 2004 and 2008), and given that recent DENV1 full genome samples from Peru are not available, we cannot exclude with certainty the role that Peru may have played in the DENV1 introductions into Ecuador. However, the results suggest a close genetic relationship of viruses circulating in Venezuela and Colombia and support the notion of commonly occurring DENV1 flow between the countries. Similar to DENV1, DENV2 genomes from Ecuador were most closely related to genomes from Venezuela and Colombia. However, unlike DENV1, DENV2 genomes from Ecuador made up a single monophyletic clade separated from the rest of the South American taxa with high support. This indicates a single introduction and subsequent spread of this virus in Ecuador without further DENV2 introductions and mixing from other regions. Even though older sequences from Peru clustered further away from genomes sampled in Ecuador, Venezuela, and Colombia, suggesting they did not play a role in the current DENV2 epidemic in Ecuador, the lack of recent full genomes from Peru prevent us from determining the involvement of Peru in the observed DENV2 spread in Ecuador. The unavailability of recent full genomes from countries surrounding Ecuador was most evident in DENV4, where the exact placement of the only Ecuadorian genome in the tree could not be determined due to low node support. Nevertheless, the results suggested a close relationship between DENV4 in Ecuador, Venezuela, Colombia and Brazil. It is important to note that samples from Peru were missing here as well, and that there is a possibility this country was also involved in the circulation of DENV4 in this region. Thus, our results suggest frequent flow of DENV between Ecuador and surrounding countries, including introduction and re-introduction of different serotypes and different lineages of the same serotype. In addition, our results show the importance of continuous surveillance, including genetic sequencing efforts. If available,

virus full genomes from these countries would allow for more accurate analysis of the patterns of DENV movement and spread in this region.

Public health implications

This study contributes to a long-term collaboration with the MoH and other governmental and academic partners to strengthen infectious disease surveillance in southern coastal Ecuador, a strategic area to monitor endemic and emerging pathogens. The collaboration has been successful due to a shared vision for integrated active surveillance that includes the virus, vector, climate and other social-ecological drivers; ongoing training of physicians, researchers and students; and improvement of local diagnostic and research infrastructure.

Enhanced surveillance studies, such as this, provide high-resolution spatiotemporal data on the distribution of symptomatic and subclinical arboviral infections across the population. This is especially important in places and in subgroups with low healthcare seeking behavior, which result in underreporting and continued disease transmission.[18,66] Enhanced surveillance systems have been shown to detect an increase in infections earlier than passive surveillance systems,[24] providing a warning of an escalating outbreak. These data are currently being used to parameterize and calibrate local epidemic forecast models.[67] These data also allow the public health sector to more accurately estimate the social and economic cost of the disease, allowing for informed decision making regarding the allocation of scarce resources for current and future interventions, such as vector control, community mobilization, and vaccines. The age-stratified prevalence data generated through this study design also provides important information for the design of vaccine trials and vaccination campaigns.

Acknowledgements. This project was possible thanks to support from colleagues from the Ministry of Health, the National Institute of Meteorology and Hydrology, the National Secretary of Higher Education, Science, Technology, and Innovation (SENESCYT) of Ecuador and community members from Machala, Ecuador. We thank our local field team and coordinators for their dedication and perseverance: Jefferson Adrian, Victor Arteaga, Jose Cueva, Reagan Deming, Carlos Enriquez, Prissila Fernandez, Froilan Heras, Naveed Heydari, Jesse Krisher, Lyndsay Krisher, Elizabeth McMahon, Eunice Ordoñez, and Tania Ordoñez. Many thanks to Rosemary Rochford, Lisa Ware, Holly Chanatry, David Amberg and Marti Benedict for supporting the development of the research platform with partners in Ecuador. We also thank Danielle Safaty and Laura Sorenson in the Center for Global Health and Translational Science at SUNY Upstate Medical University for technical support in sample preparation, RT-PCR analysis, and data compilation. We also thank Dr. Renato Leon for supporting the development of the entomology protocol, and Ing. Raul Mejia and Dr. Angel Muñoz for supporting climate surveillance. Thank you to Dr. Butsaya Thaisomboonsuk PhD and Dr. Louis Macareo MD, JD from AFRIMS for sharing surveillance and diagnostic protocols. Thank you to Clinical Research Management (CRM) for supporting continued surveillance activities.

Disclaimer. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting the views of the Department of the Army, or the Department of Defense.

Disclosures. The authors declare no competing interests, financial or non-financial.

Financial support. This study was supported in part by the Department of Defense Global Emerging Infection Surveillance (GEIS) grant (P0220_13_OT) and the Department of Medicine of SUNY Upstate Medical University. AMS and SJR were additionally supported by NSF DEB EEID 1518681 and NSF DEB RAPID 1641145. Additional support was provided to AMSI through the Prometeo program of the National Secretary of Higher Education, Science, Technology, and Innovation (SENESCYT) of Ecuador.

Current addresses of co-authors:

Sadie J. Ryan (sjryan@ufl.edu): Department of Geography, University of Florida, Gainesville, FL, USA

Aileen Kenneson (aileen.kenneson@yahoo.com): U.S. Centers for Disease Control, Atlanta, GA, USA

Timothy P. Endy (endyt@upstate.edu), Christine A. King (kingch@upstate.edu), and Arturo Barbachano-Guerrero (barbacha@upstate.edu): Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA

Mark Polhemus (polhemum@upstate.edu), Cinthya Cueva (cinthya.cueva10@gmail.com), Christina D. Lupone (luponec@upstate.edu) and Mark Abbott (abbottm@upstate.edu): Center for Global Health & Translational Sciences, SUNY Upstate Medical University, Syracuse, NY, USA

Efraín Beltrán-Ayala (felixbeltran57@hotmail.com): Department of Medicine, Universidad Técnica de Machala, Machala, El Oro Province, Ecuador

Mercy J. Borbor-Cordova (meborbor@espol.edu.ec) and Washington B. Cárdenas (wbcarden@espol.edu.ec): Department of Marine Engineering, oceanic and biological sciences, and natural resources. Escuela Superior Politecnica del Litoral (ESPOL), Guayaquil, Ecuador

Richard G. Jarman (richard.g.jarman.mil@mail.mil) and Irina Maljkovic Berry (irina.maljkovicberry.ctr@mail.mil): Viral Diseases Branch of the Walter Reed Army Institute of Research (WRAIR), Silver Springs, MD, USA

Saurabh Mehta (smehta@cornell.edu) and Julia L. Finkelstein (jfinkelstein@cornell.edu): Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA

Mercy Silva (mercysilvab@hotmail.com): Ministry of Health, Machala, El Oro, Ecuador

References

1. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control*. World Health Organization; 2009.

2. Dick OB, Martín JLS, Montoya RH, Diego J del, Zambrano B, Dayan GH. The History of Dengue Outbreaks in the Americas. *Am J Trop Med Hyg*. 2012;87(4):584-593. doi:10.4269/ajtmh.2012.11-0770.

3. San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan GH, Guzmán MG. The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality. *Am J Trop Med Hyg*. 2010;82(1):128-135. doi:10.4269/ajtmh.2010.09-0346.

4. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, Hay SI, Bedi N, Bensenor IM, Castañeda-Orjuela CA, Chuang T-W, Gibney KB, Memish ZA, Rafay A, Ukwaja KN, Yonemoto N, Murray CJL. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016. 16(6):712-723. doi:10.1016/S1473-3099(16)00026-8.

5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O. The global distribution and burden of dengue. *Nature*. 2013; 496:504-507.

6. Dengue and severe dengue. World Health Organization. http://www.who.int/mediacentre/factsheets/fs117/en/. Accessed June 11, 2014.

7. Number of Reported Cases of Chikungunya Fever in the Americas, by Country or Territory.. Pan America Health Organization. http://www.paho.org/hq/index.php?option=com_topics&view=readall&cid=5927&Itemid=40931&lang=en. Accessed February 24, 2016.

8. Zanluca C, Melo VCA de, Mosimann ALP, Santos GIV dos, Santos CND dos, Luz K, Zanluca C, Melo VCA de, Mosimann ALP, Santos GIV dos, Santos CND dos, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Mem Inst Oswaldo Cruz*. 2015;110(4):569-572. doi:10.1590/0074-02760150192.

9. Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. *Emerg Infect Dis*. 2015;21(10):1885-1886. doi:10.3201/eid2110.150847.

10. Zika cases and congenital syndrome associated with Zika virus reported by countries and territories in the Americas, 2015 - 2017. Cumulative cases. Pan American Health Organization http://www.paho.org/hq/index.php?option=com_content&view=article&id=12390&Itemid=42090&lang=en. Accessed September 22, 2016.

11. Camargo S. History of *Aedes aegypti* eradication in the Americas. *Bull World Health Organ*. 1967;36(4):602.

12. Gonzalez V, Jurado H. *Guayaquil: Aedes Aegypti, 1740 - 2007*. Guayaquil, Ecuador: Servicio Nacional para La Eradicaccion de Malaria (SNEM); 2007.

13. Dengue Epidemic - Ecuador 1988. *Mortal Morb Wkly Rep*. 38(24):419-421.

14. Alava, A., Mosquera, C., Vargas, W., Real, J. Dengue en el Ecuador 1989-2002. *Rev Ecuat Hig Med Trop*. 2005;42:11-34.

15. *Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas by Country*. Pan American Health Organization. http://www.paho.org/hq/index.php?option=com_topics&view=rdmore&cid=6290&Itemid=40734&lang=en Accessed September 22, 2017.

16. Stewart Ibarra AM, Lowe R. Climate and non-climate drivers of dengue epidemics in southern coastal Ecuador. *Am J Trop Med Hyg*. 2013;88(5):971-981. doi:10.4269/ajtmh.12-0478.

17. Stewart Ibarra AM, Ryan SJ, Beltrán E, Mejía R, Silva M, Muñoz Á. Dengue Vector Dynamics (*Aedes aegypti*) Influenced by Climate and Social Factors in Ecuador: Implications for Targeted Control. *PLOS ONE*. 2013;8(11):e78263.

18. Stewart Ibarra AM, Luzadis VA, Borbor-Cordova M, Silva M, Ordonez T, Beltran Ayala, Efrain, Ryan SJ. A social-ecological analysis of community perceptions of dengue fever and *Aedes aegypti* in Machala, Ecuador. *BMC Public Health*. 2014;(14):1135. doi:10.1186/1471-2458-14-1135.

19. Stewart Ibarra AM, Munoz AG, Ryan SJ, Borbor MJ, Ayala EB, Finkelstein JL, Mejia R, Ordonez T, Coronel GCR, Rivero K. Spatiotemporal clustering, climate periodicity, and social-ecological risk factors for dengue during an outbreak in Machala, Ecuador, in 2010. *BMC Infect Dis*. 2014;14:610. doi:10.1186/s12879-014-0610-4.

20. Anders KL, Van Thuy NT, Van Ngoc T, Tam CT, Tai LTH, Truong NT, Le Duyen HT, Trung VT, Kien DTH, Wolbers M, others. Households as foci for dengue transmission in highly urban Vietnam. *PLoS Negl Trop Dis*. 2015;9(2):e0003528.

21. Yoon I-K, Getis A, Aldstadt J, Rothman AL, Tannitisupawong D, Koenraadt CJM, Fansiri T, Jones JW, Morrison AC, Jarman RG, Nisalak A, Mammen MP Jr, Thammapalo S, Srikiatkhachorn A, Green S, Libraty DH, Gibbons RV, Endy T, Pimgate C, Scott TW. Fine Scale Spatiotemporal Clustering of Dengue Virus Transmission in Children and *Aedes aegypti* in Rural Thai Villages. *PLoS Negl Trop Dis*. 2012;6(7):e1730. doi:10.1371/journal.pntd.0001730.

22. Mammen Jr MP, Pimgate C, Koenraadt CJ, Rothman AL, Aldstadt J, Nisalak A, Jarman RG, Jones JW, Srikiatkhachorn A, Ypil-Butac CA. Spatial and temporal clustering of dengue virus transmission in Thai villages. *PLoS Med*. 2008;5(11):e205.

23. Thomas SJ, Aldstadt J, Jarman RG, Buddhari D, Yoon I-K, Richardson JH, Ponlawat A, Iamsirithaworn S, Scott TW, Rothman AL, others. Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy. *Am J Trop Med Hyg*. 2015;93(1):24–32.

24. Olkowski S, Stoddard ST, Halsey ES, Morrisson AC, Barker CM, Scott TW. Sentinel versus passive surveillance for measuring changes in dengue incidence: Evidence from three concurrent surveillance systems in Iquitos, Peru. *bioRxiv*. February 2016:40220. doi:10.1101/040220.

25. Rocha C, Morrison AC, Forshey BM, Blair PJ, Olson JG, Stancil JD, Sihuincha M, Scott TW, Kochel TJ. Comparison of Two Active Surveillance Programs for the Detection of Clinical Dengue Cases in Iquitos, Peru. *Am J Trop Med Hyg*. 2009;80(4):656-660.

26. Ramos MM, Argüello DF, Luxemburger C, Quiñones L, Muñoz JL, Beatty M, Lang J, Tomashek KM. Epidemiological and Clinical Observations on Patients with Dengue in Puerto Rico: Results from the First Year of Enhanced Surveillance—June 2005–May 2006. *Am J Trop Med Hyg*. 2008;79(1):123-127. doi:10.4269/ajtmh.2008.79.123.

27. Restrepo BN, Piedrahita LD, Agudelo IY, Parra-Henao G, Osorio JE. Frequency and clinical features of dengue infection in a schoolchildren cohort from Medellin, Colombia. *J Trop Med*. 2012;2012. https://www.hindawi.com/journals/jtm/2012/120496/abs/. Accessed May 11, 2017.

28. Espino C. Active surveillance and incidence rate of dengue infection in a cohort of high risk population in Maracay, Venezuela. 2010. http://scholarcommons.usf.edu/etd/1626/. Accessed May 11, 2017.

29. Kuan G, Gordon A, Avilés W, Ortega O, Hammond SN, Elizondo D, Nuñez A, Coloma J, Balmaseda A, Harris E. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods,

Use of Information Technology, and Extension to Other Infectious Diseases. *Am J Epidemiol*. 2009;170(1):120-129. doi:10.1093/aje/kwp092.

30. Borbor-Cordova M, Beltran Ayala E, Cardenas W, Endy TP, Finkelstein JL, King CA, Leon R, Muñoz ÁG, Mejia R, Polhemus ME, Recalde-Coronel GC, Ryan SJ, Stewart Ibarra AM. Case study 5.C Vector-virus microclimate surveillance system for dengue control in Machala, Ecuador. In: *Climate Services for Health: Improving Public Health Decision-Making in a New Climate*. Geneva, Switzerland: World Meteorological Association and World Health Organization; 2016. http://public.wmo.int/en/resources/library/climate-services-health-case-studies. Accessed September 3, 2016.

31. Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, Rothman AL, Vaughn DW, Ennis FA. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. *Am J Epidemiol*. 2002;156(1):40–51.

32. Sommerfeld J, Kroeger A. Eco-bio-social research on dengue in Asia: a multicountry study on ecosystem and community-based approaches for the control of dengue vectors in urban and peri-urban Asia. *Pathog Glob Health*. 2012;106(8):428-435. doi:10.1179/2047773212Y.0000000055.

33. Quintero J, Brochero H, Manrique-Saide P, Barrera-Pérez M, Basso C, Romero S, Caprara A, Cunha JCDL, Ayala EB-, Mitchell-Foster K, Kroeger A, Sommerfeld J, Petzold M. Ecological, biological and social dimensions of dengue vector breeding in five urban settings of Latin America: a multi-country study. *BMC Infect Dis*. 2014;14(1):38. doi:10.1186/1471-2334-14-38.

34. *Casos de Dengue Reportados En El Epi Local Por Semanas Epidemiologicas*. Machala, Ecuador: Departamento de Epidemiologia, Direccion Provincial de Salud de El Oro, Ministerio de Salud Publica; 2010.

35. Pan-ngum W, Blacksell SD, Lubell Y, Pukrittayakamee S, Bailey MS, de Silva HJ, Lalloo DG, Day NPJ, White LJ, Limmathurotsakul D. Estimating the True Accuracy of Diagnostic Tests for Dengue Infection Using Bayesian Latent Class Models. *PLoS ONE*. 2013;8(1). doi:10.1371/journal.pone.0050765.

36. Pal S, Dauner AL, Valks A, Forshey BM, Long KC, Thaisomboonsuk B, Sierra G, Picos V, Talmage S, Morrison AC, Halsey ES, Comach G, Yasuda C, Loeffelholz M, Jarman RG, Fernandez S, An US, Kochel TJ, Jasper LE, Wu S-JL. Multicountry Prospective Clinical Evaluation of Two Enzyme-Linked Immunosorbent Assays and Two Rapid Diagnostic Tests for Diagnosing Dengue Fever. *J Clin Microbiol*. 2015;53(4):1092-1102. doi:10.1128/JCM.03042-14.

37. Santiago GA, Vergne E, Quiles Y, Cosme J, Vazquez J, Medina JF, Medina F, Colón C, Margolis H, Muñoz-Jordán JL. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. *PLoS Negl Trop Dis*. 2013;7(7):e2311.

38. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis*. 2008;14(8):1232–9.

39. Toan NT, Rossi S, Prisco G, Nante N, Viviani S. Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting. *Trop Med Int Health*. 2015;20(7):840–863.

40. Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden of dengue in Southeast Asia: a systematic analysis. *PLoS Negl Trop Dis*. 2013;7(2):e2056.

41. Runge-Ranzinger S, McCall PJ, Kroeger A, Horstick O. Dengue disease surveillance: an updated systematic literature review. *Trop Med Int Health*. 2014;19(9):1116–1160.

42. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014:btu170.

43. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *ArXiv Prepr ArXiv13033997*. 2013. http://arxiv.org/abs/1303.3997. Accessed November 11, 2016.

44. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, others. The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009;25(16):2078–2079.

45. Hunter JD, others. Matplotlib: A 2D graphics environment. *Comput Sci Eng*. 2007;9(3):90–95.

46. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*. 2013;30(12):2725–2729.

47. Myers WGWME, Altschul SF, Lipman DJ. Basic local alignment search tool. *J Mol Biol*. 1990;215(3):403–10.

48. Posada D. jModelTest: phylogenetic model averaging. *Mol Biol Evol*. 2008;25(7):1253–1256.

49. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. *Syst Biol*. 2003;52(5):696–704.

50. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol*. 2010;59(3):307–321.

51. Pyke AT, Moore PR, Taylor CT, Hall-Mendelin S, Cameron JN, Hewitson GR, Pukallus DS, Huang B, Warrilow D, van den Hurk AF. Highly divergent dengue virus type 1 genotype sets a new

distance record. *Sci Rep*. 2016;6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770315/. Accessed November 11, 2016.

52. Widjaja S, Listiyaningsih E, Ma'roef C, Wuryadi S, Bangs MJ, Samsi TK, Yuwono D, Hayes CG, Porter KR. Early detection of dengue infections using cluster sampling around index cases. *DENGUE Infect WEST JAVA Indones Curr Situat Chall*.:195.

53. Standish K, Kuan G, Avilés W, Balmaseda A, Harris E. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. *PLoS Negl Trop Dis*. 2010;4(3):e633. doi:10.1371/journal.pntd.0000633.

54. Lustig Y, Mendelson E, Paran N, Melamed S, Schwartz E. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. *Eurosurveillance*. 2016;21(26). http://www.e-sciencecentral.org/articles/SC000017361. Accessed May 11, 2017.

55. Gourinat A-C, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika Virus in Urine. *Emerg Infect Dis*. 2015;21(1):84-86. doi:10.3201/eid2101.140894.

56. Ali A, ur Rehman H, Nisar M, Rafique S, Ali S, Hussain A, Idrees M, Sabri S, Zada H, Hussain S, others. Seroepidemiology of dengue fever in Khyber Pakhtunkhawa, Pakistan. *Int J Infect Dis*. 2013;17(7):e518–e523.

57. Fernández E, Smieja M, Walter SD, Loeb M. A predictive model to differentiate dengue from other febrile illness. *BMC Infect Dis*. 2016;16(1):694.

58. Zim MM, Sam I-C, Omar SS, Chan YF, AbuBakar S, Kamarulzaman A. Chikungunya infection in Malaysia: comparison with dengue infection in adults and predictors of persistent arthralgia. *J Clin Virol*. 2013;56(2):141–145.

59. Murray KO, Rodriguez LF, Herrington E, Kharat V, Vasilakis N, Walker C, Turner C, Khuwaja S, Arafat R, Weaver SC, others. Identification of dengue fever cases in Houston, Texas, with evidence of autochthonous transmission between 2003 and 2005. *Vector-Borne Zoonotic Dis*. 2013;13(12):835–845.

60. Parreira R, Conceição C, Centeno-Lima S, Marques N, da Cunha JS, Abreu C, Sá L, Sarmento A, Atouguia J, Moneti V, others. Angola's 2013 dengue outbreak: clinical, laboratory and molecular analyses of cases from four Portuguese institutions. *J Infect Dev Ctries*. 2014;8(9):1210–1215.

61. Thai KT, Phuong HL, Nga TTT, Giao PT, Hung LQ, Van Nam N, Binh TQ, Simmons C, Farrar J, Hien TT, others. Clinical, epidemiological and virological features of Dengue virus infections in Vietnamese patients presenting to primary care facilities with acute undifferentiated fever. *J Infect*. 2010;60(3):229–237.

62. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, Sahoo MK, Nuñez A, Balmaseda A, Harris E, Pinsky BA. Viremia and Clinical Presentation in Nicaraguan Patients Infected with Zika Virus, Chikungunya Virus, and Dengue Virus. *Clin Infect Dis*. August 2016:ciw589. doi:10.1093/cid/ciw589.

63. Thomas L, Verlaeten O, Cabié A, Kaidomar S, Moravie V, Martial J, Najioullah F, Plumelle Y, Fonteau C, Dussart P, others. Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic. *Am J Trop Med Hyg*. 2008;78(6):990–998.

64. Le Gonidec E, Maquart M, Duron S, Savini H, Cazajous G, Vidal P-O, Chenilleau M-C, Roseau J-B, Benois A, Dehan C, others. Clinical Survey of Dengue Virus Circulation in the Republic of Djibouti between 2011 and 2014 Identifies Serotype 3 Epidemic and Recommends Clinical Diagnosis Guidelines for Resource Limited Settings. *PLoS Negl Trop Dis*. 2016;10(6):e0004755.

65. Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, Hammond SN, Nuñez A, Avilés W, Henn MR, Holmes EC, Gordon A, Coloma J, Kuan G, Harris E. Trends in patterns of dengue transmission over four years of a pediatric cohort study in Nicaragua. *J Infect Dis*. 2010;201(1):5-14. doi:10.1086/648592.

66. Handel AS, Ayala EB, Borbor-Cordova MJ, Fessler AG, Finkelstein JL, Espinoza RXR, Ryan SJ, Stewart-Ibarra AM. Knowledge, attitudes, and practices regarding dengue infection among public sector healthcare providers in Machala, Ecuador. *Trop Dis Travel Med Vaccines*. 2016;2:8. doi:10.1186/s40794-016-0024-y.

67. Lowe R, Stewart-Ibarra AM, Petrova D, García-Díez M, Borbor-Cordova MJ, Mejía R, Regato M, Rodó X. Climate services for health: predicting the evolution of the 2016 dengue season in Machala, Ecuador. *Lancet Planet Health*. 2017;1(4):e142-e151. doi:10.1016/S2542-5196(17)30064-5.



Fig 1: Map of the study site: A. Location of Ecuador in the Americas. B. Location of El Oro Province in Ecuador, the city of Machala indicated as a red dot. C. The city of Machala, showing the five Ministry of Health clinical sites/hospital: 1. Mabel Estupiñan Clinic, 2. Teofilo Davila Hospital, 3. Brisas del Mar Clinic, 4. El Paraiso Clinic, 5. Rayito de Luz Clinic. The location of meteorological stations are indicated by A-E as follows: A. Puerto Bolivar, B. Los Esteros, C. Mabel Estupiñan; D. Florida; E. Crucitas.



Fig 2. Study design. DENV surveillance study design in Machala, Ecuador, in 2014 and 2015.



Fig 3. Weekly acute DENV and CHIKV infections in 2014 and 2015 detected by passive and active surveillance. Note: no surveillance was conducted in week 30 of 2014.



Fig 4. The prevalence of febrile acute DENV and CHIKV infections by age class. We calculated the prevalence of febrile acute (FA) infections as the total number of individuals with FA infections divided by all individuals from the age class who were recruited into the study and had valid diagnostic results, demographic data, and symptom data. (A) Index cases with FA infections for DENV and CHIKV; (B) Associates with FA DENV infections. There were no associates with a FA CHIKV infection. For DENV, data are shown for 2014 and 2015. For CHIKV, data are shown only for 2015. Febrile defined as temperature measured > 38°C upon recruitment, or self-reported fever within the last 7 days. See Supplemental Table 5 for raw data.

Fig 5. **Maximum likelihood phylogenetic tree of DENV1 genotypes from Ecuador in 2014**. Samples from Ecuador are colored magenta (dark and light). The two clades containing the genomes from Ecuador are marked in the tree (A and B). aLRT confidence values are shown next to the respective node. The tree is rooted on the sylvatic genotype *VI* sample. Some clades were collapsed in the tree to increase clarity. All collapsed clades were supported with high (>0.75) aLRT values and contained only genomes from a single country, indicated in the name of the clade. Colored taxa represent known genotype references.



Fig 6. Maximum likelihood phylogenetic tree of DENV2 genotypes from Ecuador in 2014. Samples from Ecuador are colored magenta in a monophyletic clade A. aLRT confidence values are shown next to the respective node. The tree is rooted on the sylvatic genotype outgroup. Some clades were collapsed in the tree to increase clarity. All collapsed clades were supported with high (>0.75) aLRT values and contained only genomes from a single country, indicated in the name of the clade. Colored taxa represent known genotype references.



Fig 7. Maximum likelihood phylogenetic tree of DENV4 genotypes from Ecuador in 2014. Sample from Ecuador is colored in magenta. aLRT confidence values are shown next to the respective node. Low aLRT values are highlighted in red. The tree is rooted on the sylvatic genotype outgroup. Some clades were collapsed in the tree to increase clarity. All collapsed clades were supported with high (>0.75) aLRT values and contained only genomes from a single country, indicated in the name of the clade. Colored taxa represent known genotype references.

Table 1. Demographic data and infection status of index cases and associates. The characteristics of index cases and associates in 2014 and 2015: mean age (standard deviation = SD) and gender, febrile status, and arbovirus infection status (DENV acute infection: NS1 RT, NS1 ELISA or RT-PCR positive; DENV recent infection: IgM positive and NS1 RT/NS1 ELISA/RT-PCR negative; CHIKV and ZIKV confirmed by RT-PCR).

	2014		**2015**	
	Index cases	**Associates**	**Index cases**	**Associates**
	N = 186	**N = 298**	**N = 124**	**N = 86**
Age in years, mean (SD)	20.58 (15.5)	35.28 (19.1)	27.97 (18.6)	38.79 (20.0)
Gender, % female	90/186 (48.4%)	195/295 (66.1%)	68/124 (54.8%)	58/86 (67.4%)
Temperature > 38°C	30/185* (16.2%)	2/290 (0.7%)	23/124 (18.5%)	0/86 (0%)
Fever in the last 7 days	179/185 (96.8%)	33/285 (11.6%)	119/124 (96.0%)	3/83 (3.6%)
DENV infection				
Acute infection	75/186 (40.3%)	45/298 (15.1%)	24/124 (19.4%)	5/86 (5.8%)
Recent infection	57/186 (30.6%)	61/298 (20.5%)	11/124 (8.9%)	6/86 (7.0%)
Other acute infections				
Chikungunya virus	0/152 (0%)	Not Tested	50/122 (41%)	4/87 (4.6%)
Zika virus	Not tested	Not tested	0/122 (0%)	0/87 (0%)

*Note that sample sizes change due to missing data.

Table 2. DENV serotypes in 2014 and 2015. Results from the analysis of samples from 69 individuals in 2014 and 23 individuals in 2015 who were serotyped for DENV by RT-PCR. In 2014, all four DENV serotypes were detected, with DENV2 as the predominant serotype. One index case in 2014 was positive for DENV1 and DENV2. In 2015, DENV1 and DENV2 co-circulated.

	2014		**2015**	
DENV serotypes	**Index cases N = 51**	**Associates N = 18**	**Index cases N = 22**	**Associates N = 1**
1	4/51 (7.8%)	3/18 (16.7%)	13/22 (59.1%)	0/1 (0%)
1 & 2	1/51 (2.0%)	0/18 (0%)	0/22 (0%)	0/1 (0%)
2	43/51 (84.3%)	10/18 (55.6%)	9/22 (40.9%)	1/1 (100%)
3	2/51 (3.9%)	5/18 (27.8%)	0/22 (0%)	0/1 (0%)
4	1/51 (2.0%)	0/18 (0%)	0/22 (0%)	0/1 (0%)

Table 3. DENV serology results for index cases and associates. Secondary DENV infections were more prevalent in 2014, whereas primary DENV infections were more prevalent in 2015. The serology of index cases in 2014 versus 2015 was significantly different ($p<0.001$). The serology of associates in 2014 versus 2015 was not significantly different ($p>0.05$). Results are shown for all individuals who had valid serology results.

	2014		**2015**	
Serology	**Index cases**	**Associates**	**Index cases**	**Associates**
	N = 99	**N = 81**	**N = 31**	**N = 6**
Primary DENV infection	26 (26.3%)	38 (46.9%)	21 (67.7%)	4 (66.7%)
Secondary DENV infection	73 (73.7%)	43 (53.0%)	10 (32.2%)	2 (33.3%)

Table 4. Characteristics of acute DENV infections. Index cases and associates with acute DENV infections in 2014 and 2015: mean age (standard deviation = SD) and gender, febrile status, proportion that were hospitalized, serology (primary versus secondary infections), and DENV serotypes (DENV1-4, one person positive for DENV1 and DENV2). For all measures, there were no significant differences between years ($p<0.05$).

	2014		**2015**	
	Index cases	**Associates**	**Index cases**	**Associates**
	N = 75	**N = 45**	**N = 24**	**N = 5**
Age in years, mean (SD)	20.67 (15.7)	25.02 (18.6)	19.33 (12.8)	19.6 (14.6)
Gender, % female	28/75 (37.3%)	29/45 (64.4%)	13/24 (54.1%)	2/4 (50%)
Temperature > 38°C	16/75 (21.3%)	2/43 (4.7%)	10/24 (41.7%)	0/5 (0%)
Fever in the last 7 days	73/75 (97.3%)	10/41 (24.4%)	24/24 (100%)	1/5 (20%)
Hospitalized	12/66 (18.2%)	0/45 (0%)	8/24 (33.3%)	0/5 (0%)

Table 5. Demographics and symptoms associated with acute DENV infections versus CHIKV infections in index cases. Index cases with acute DENV infections were significantly younger and more likely to report anorexia and nausea, vomiting and abdominal pain ($p<0.05$). Index cases with CHIKV were older and more likely to report rash ($p<0.05$). Individuals with DENV and CHIKV co-infections were excluded.

	Acute DENV N = 98	**Acute CHIKV N = 48**	**p-value**
Age in years, mean (SD)	20.22 (15.0)	35.38 (18.2)	**<0.0001**
Gender, % female	41/98 (41.8%)	33/48 (68.8%)	0.22
Temperature > 38°C	26/98 (26.5%)	6/48 (12.5%)	0.09
Hospitalized	20/89 (22.5%)	5/48 (10.4%)	0.22
Symptoms in prior 7 days			
Fever	97/98 (98.98%)	46/48 (95.8%)	0.52
Headache	80/97 (82.5%)	35/47 (74.5%)	0.37
Anorexia and nausea	64/98 (65.3%)	18/48 (37.5%)	**0.003**
Muscle/joint pain	75/97 (77.3%)	46/48 (95.8%)	0.14
Rash	16/97 (16.5%)	17/48 (35.4%)	**0.02**
Bleeding	8/98 (8.2%)	2/48 (4.2%)	0.58
Rhinorrhea	15/98 (15.3%)	5/49 (10.4%)	0.55
Vomiting	46/98 (46.9%)	12/48 (25.0%)	**0.005**
Drowsiness/lethargy	82/98 (93.9%)	43/48 (89.6%)	0.48
Cough	27/98 (27.6%)	6/48 (12.5%)	0.08
Abdominal pain	62/97 (63.9%)	18/48 (37.5%)	**0.005**
Diarrhea	27/98 (27.6%)	16/48 (33.3%)	0.38
Retro-orbital pain	67/98 (68.4%)	33/47 (70.2%)	0.97

Table 6. Expansion factor (EF) estimates for DENV infections. EFs provide an estimate of the number of additional infections in the community not detected by traditional passive surveillance methods. In 2014 and 2015, mean EFs and standard deviations (SD) were calculated for acute and recent DENV infections, for acute DENV infections, and for symptomatic acute DENV infections. EFs were significantly greater in 2014 than in 2015 ($p<0.05$).

Mean EFs (SD)	**2014**	**2015**	**p-value**
Acute and recent infections	3.14 (2.22)	0.92 (0.67)	< 0.001
Acute infections	1.33 (1.49)	0.42 (0.67)	0.016
Symptomatic acute infections	0.89 (1.05)	0.25 (0.62)	0.03

Supplementary Table 1. Symptoms of associates with acute DENV infections. Dengue-like symptoms include all symptoms listed below except for cough and rhinorrhea.

	N=50	**Prevalence**
Any dengue-like symptom	34	68%
Temperature > 38°C	2	4%
Symptoms in prior 7 days		
Headache	16	32%
Drowsiness/lethargy	12	24%
Fever	11	22%
Muscle/joint pain	11	22%
Retro-orbital pain	11	22%
Abdominal pain	9	18%
Rash	9	18%
Anorexia and nausea	5	10%
Diarrhea	3	6%
Vomiting	2	4%
Bleeding	1	2%
Cough	*7*	*14%*
Rhinorrhea	*5*	*10%*

Supplementary Table 2. (A) Primers and (b) probes used for RT-PCR diagnostics of DENV, CHIKV, and ZIKV.

A. Primers

Viral Target	Primer Name	Primer Sequence 5' to 3'
DENV1	D1F	CAAAAGGAAGTCGYGCAATA
DENV1	D1R	CTGAGTGAATTCTCTCTGCTRAAC
DENV2	D2F	CAGGCTATGGCACYGTCACGAT
DENV2	D2R	CCATYTGCAGCARCACCATCTC
DENV3	D3F	GGACTRGACACACGCACCCA
DENV3	D3R	CATGTCTCTACCTTCTCGACTTGYCT
DENV4	D4F	TTGTCCTAATGATGCTRGTCG
DENV4	D4R	TCCACCYGAGACTCCTTCCA
CHIKV	CHIKF_856	ACCATCGGTGTTCCATCTAAAG
CHIKV	CHIKR_962c	GCCTGGGCTCATCGTTATT
ZIKA	ZIKAF_1086	CCGCTGCCCAACACAAG
ZIKA	ZIKAR_1162c	CCACTAACGTTC TTTTGCAGACAT

B. Probes

Viral Target	Probe Name	Probe Sequence 5' to 3'	5' Label	3' Quench
DENV1	D1P	CATGTGGYTGGGAGCRCGC	FAM	BHQ1
DENV2	D2P	CTCYCCRAGAACGGGCCTCGACTTCAA	HEX	BHQ1
DENV3	D3P	ACCTGGATGTCGGCTGAAGGAGCTTG	TexRed	BHQ2
DENV4	D4P	TYCCTACYCCTACGCATCGCATTCCG	Cy5	BHQ3
CHIKV	CHIKP_908	ACAGTGGTT/ZEN/TCGTGTGAGGGCTAC	HEX	IBFQ
ZIKA	ZIKAP_1107	AGCCTACCT/ZEN/TGACAAGCAGTCAGACACTCAA	FAM	IBFQ

Supplementary Table 3. The prevalence of febrile acute DENV and CHIKV infections in index cases and associates by age class. Data were used to generate Figure 4. Index cases and associates with febrile acute infections (FA) for DENV or CHIKV, as a proportion of all individuals from the age class who were recruited into the study (N). For DENV, data are combined for 2014 and 2015. For CHIKV, data are shown only for 2015. Febrile defined as temperature measured > 38°C upon recruitment, or self-reported fever within the last 7 days.

	Index cases DENV			**Associates DENV**			**Index cases CHIKV**			**Associates CHIKV**		
Age class	FA	N		FA	N		FA	N		FA	N	
0-9	23	74	31.1%	3	25	12.0%	5	22	22.7%	0	3	0.0%
10-19	40	98	40.8%	5	70	7.1%	7	28	25.0%	0	17	0.0%
20-29	13	51	25.5%	2	65	3.1%	8	25	32.0%	0	14	0.0%
30-39	9	39	23.1%	1	61	1.6%	7	16	43.8%	0	13	0.0%
40-49	6	25	24.0%	0	62	0.0%	9	14	64.3%	0	13	0.0%
50-59	7	22	31.8%	0	47	0.0%	7	10	70.0%	0	10	0.0%
60-69	0	8	0.0%	0	36	0.0%	5	5	100.0%	0	9	0.0%
70-90	0	4	0.0%	0	19	0.0%	0	2	0.0%	0	8	0.0%
Total	98	321	30.5%	11	385	2.9%	48	122	39.3%	0	87	0.0%

Supplementary Table 4. Demographics and symptoms associated with primary versus secondary DENV infections in index cases. Index cases with primary DENV infections were significantly younger, were less likely to be hospitalized, were more likely to have a fever, and were less likely to report vomiting ($p<0.05$). Index cases with DENV and CHIKV co-infections were excluded.

	Primary infections	**Secondary infections**	**p-value**
	N = 43	**N = 82**	
Age in years, mean (SD)	18.0 (13.1)	23.2 (13.8)	**0.046**
Gender, % female	19/43 (44.2%)	41/82 (50.0%)	0.53
Temperature > 38°C	10/39 (25.6%)	7/79 (8.86%)	**0.01**
Hospitalized	4/37 (10.8%)	33/75 (44.0%)	**0.0005**
Symptoms in prior 7 days			
Fever	42/43 (97.7%)	77/81 (95.1%)	0.66
Headache	37/43 (86.0%)	62/82 (75.6%)	0.17
Anorexia and nausea	27/143 (62.8%)	53/82 (64.6%)	0.84
Muscle/joint pain	33/43 (76.7%)	62/82 (75.6%)	0.89
Rash	9/42 (21.4%)	16/82 (19.5%)	0.80
Bleeding	3/42 (7.14%)	12/82 (14.6%)	0.26
Rhinorrhea	7/43 (16.3%)	11/82 (13.4%)	0.66
Vomiting	15/43 (34.9%)	45/82 (54.9%)	**0.03**
Drowsiness/lethargy	36/43 (83.7%)	74/82 (90.2%)	0.29
Cough	9/43 (20.9%)	25/82 (30.5%)	0.25
Abdominal pain	25/42 (59.5%)	53/82 (64.6%)	0.58
Diarrhea	10/43 (23.3%)	25/82 (30.5%)	0.39
Retro-orbital pain	32/43 (74.4%)	48/81 (59.3%)	0.09

Supplementary Table 5. Demographics and symptoms associated with DENV1 versus DENV2 infections in index cases. Index cases with DENV1 infections were significantly younger than those with DENV2 infections ($p<0.05$). For all other measures, there were no significant differences ($p<0.05$). Individuals with DENV and CHIKV co-infections were excluded.

	DENV1	**DENV2**	**p-value**
	N = 17	**N = 51**	
Age in years, mean (SD)	14.9 (10.8)	25.2 (16.2)	**0.02**
Gender, % female	8/17 (47.1%)	21/51 (41.2%)	0.67
Temperature > 38°C	8/16 (50%)	15/48 (31.2%)	0.16
Hospitalized	4/17 (23.5%)	7/44 (15.9%)	0.48
Symptoms in prior 7 days			
Fever	17/17 (100%)	49/51 (96.1%)	1.00
Headache	17/17 (100%)	43/51 (84.3%)	0.19
Anorexia and nausea	13/17 (76.5%)	32/51 (62.8%)	0.38
Muscle/joint pain	12/17 (70.6%)	43/51 (84.3%)	0.21
Rash	2/16 (12.5%)	8/51 (15.7%)	1.00
Bleeding	2/17 (11.8%)	2/51 (3.92%)	0.26
Rhinorrhea	3/17 (17.6%)	8/51 (15.7%)	1.00
Vomiting	9/17 (52.9%)	26/51 (51.0%)	0.89
Drowsiness/lethargy	16/17 (94.1%)	44/51 (86.3%)	0.67
Cough	3/17 (17.6%)	15/51 (29.4%)	0.53
Abdominal pain	12/17 (70.6%)	31/51 (60.8%)	0.47
Diarrhea	4/17 (23.5%)	12/51 (23.5%)	1.00
Retro-orbital pain	13/17 (76.5%)	36/51 (70.6%)	0.76
Serology			
Primary DENV infection	10/13 (76.9%)	13/32 (40.6%)	0.06
Secondary DENV infection	3/13 (23.1%)	19/32 (59.4%)	0.06